Tirelli U, Carbone A, Zagonei V, Brema F, Veronesi A, Grigoletto E, Volpe R
Am J Clin Oncol. 1985 Aug;8(4):329-31. doi: 10.1097/00000421-198508000-00011.
From September 1979 to December 1983, a phase II trial with teniposide (VM-26) in multiple myeloma (MM) was conducted at our institution. Of the 30 patients entered, 25 were evaluable for response, 12 previously treated with M-2 protocol and 13 previously untreated elderly (greater than or equal to 70 years) patients. A median of nine cycles (range 1-21) of VM-26 was administered. Seven responses (28%) according to Myeloma Task Force criteria were observed with a median duration of 4 months (range 2-12+). Four responses (33%) were observed in the 12 previously treated patients. Overall toxicity was mild. VM-26 seems an active drug in MM, without significant toxicity even in elderly patients.
1979年9月至1983年12月，我们机构开展了一项关于替尼泊苷（VM - 26）治疗多发性骨髓瘤（MM）的II期试验。入组的30例患者中，25例可评估疗效，其中12例曾接受M - 2方案治疗，13例为既往未治疗的老年（≥70岁）患者。给予VM - 26的中位疗程为9个周期（范围1 - 21个周期）。根据骨髓瘤工作组标准，观察到7例缓解（28%），中位缓解持续时间为4个月（范围2 - 12 +个月）。在12例既往接受治疗的患者中观察到4例缓解（33%）。总体毒性较轻。VM - 26似乎是治疗MM的一种有效药物，即使在老年患者中也无明显毒性。
